Infectious Diseases News and Research

RSS

Roche's MagNA Pure 96 System for nucleic acid purification evaluated

TriCore Reference Laboratories of Albuquerque, N.M., reported at a recent user meeting results of their research collaboration with Roche Applied Science in which they evaluated Roche´s new MagNA Pure 96 System for use in nucleic acid purification. The evaluation focused on the Roche system’s ability to process specimens for pathogen testing.

1 Dec 2009

Akonni Biosystems receives $3.2M Phase II SBIR grant from NIH

Akonni Biosystems, a molecular diagnostics (MDx) company focused on providing rapid and highly scalable solutions for infectious disease testing, today announced receipt of a $3.2M Phase II SBIR grant from the National Institutes of Health (NIH).

1 Dec 2009

Centura Health establishes comprehensive trauma system across its regional facilities

According to the Colorado Department of Public Health and Environment, trauma is the leading cause of death for Coloradans ages one to 44. Studies indicate that 30 to 40 percent of all trauma deaths occur within one hour of injury, and that 30 to 40 percent of these deaths are preventable if timely, appropriate care is received.

1 Dec 2009

Biomagnetics Diagnostics announces Patent License Agreement with Los Alamos National Security

Biomagnetics Diagnostics Corp. (PINK SHEETS:BMGP), a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, today announced the Company has finalized a "Patent License Agreement with Los Alamos National Security."

30 Nov 2009

Tripep completes phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that its partner Tripep AB of Sweden has completed its phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine delivered using Inovio’s electroporation technology.

30 Nov 2009

WHITIA launches digital medical X-ray device for screening infectious diseases in developing countries

The World Health Imaging, Telemedicine and Informatics Alliance (WHITIA) today unveiled Remi-d, a new product concept that is intended to provide remote-operated X-ray capabilities for use in screening across areas of the developing world experiencing the Human Immunodeficiency Virus (HIV) and Tuberculosis (TB) co-epidemic, high incidences of Black Lung disease, or outbreaks of other infectious respiratory diseases.

30 Nov 2009

Tripep completes clinical trial of ChronVac-C for Hepatitis C virus treatment

All samples from the 12 patients with chronic Hepatitis C genotype 1 treated with Tripep’s therapeutic vaccine ChronVac-C have now been collected. The treatment was found to be safe, immunogenic and had transient effects on the serum levels of hepatitis C virus.

27 Nov 2009

School closure during infectious disease pandemic reduces illness transmission

A survey carried out in eight European countries has shown that closing schools in the event of an infectious disease pandemic could have a significant role in reducing illness transmission.

27 Nov 2009

Merck, Idera Pharmaceuticals extend their vaccine research collaboration

Idera Pharmaceuticals, Inc. today announced that Merck & Co., Inc., through an affiliate, has extended its research collaboration with Idera for a fourth year. In December 2006, the companies entered into an exclusive license and research collaboration agreement to research, develop, and commercialize vaccine products containing the Company’s investigational agonist compounds targeting Toll-like Receptors (TLRs) 7, 8, and 9 in the fields of oncology, infectious diseases, and Alzheimer’s disease.

26 Nov 2009

Cells protect themselves against viruses and bacteria with novel non-genetic mechanism

When cells are confronted with an invading virus or bacteria or exposed to an irritating chemical, they protect themselves by going off their DNA recipe and inserting the wrong amino acid into new proteins to defend them against damage, scientists have discovered.

26 Nov 2009

Tibotec Therapeutics' INTELENCE granted FDA traditional approval

The FDA granted traditional approval for INTELENCE® (etravirine) tablets, a non-nucleoside reverse transcriptase inhibitor (NNRTI). INTELENCE is the only NNRTI specifically indicated for use in treatment-experienced adults who are experiencing virologic failure with HIV-1 strains resistant to an NNRTI and other antiretroviral (ARV) agents.

25 Nov 2009

WHO investigates cases of H1N1 drug resistance in U.S., Britain

The WHO is looking into reports that patients with "severely suppressed immune systems" in Britain and the U.S. developed resistance Tamiflu, which is used to treat the symptoms of H1N1 (swine flu), a spokesman for the organization said Tuesday, Reuters reports.

25 Nov 2009

Despite gains, HIV/AIDS remains public-health priority, UNAIDS, WHO say

"The U.N. report said 'AIDS continues to be a major public-health priority' and called for more funds to support efforts to curb the epidemic and to distribute lifesaving drugs," the Wall Street Journal reports.

25 Nov 2009

IES to install electrical systems at the U.S. Army Medical Research Institute of Infectious Diseases

IES, a leading national provider of electrical and communications systems and services for the commercial, industrial and residential markets, announced today that its commercial business group has been awarded a contract from Manhattan Torcon JV to install the electrical systems for the Level 4 bio-safety lab (BSL-4) replacement facility at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) at Fort Detrick in Frederick, Md.

25 Nov 2009

FDA provides marketing clearance for Prodesse's ProParaflu+ assay

Gen-Probe Incorporated announced today that the US Food and Drug Administration (FDA) has cleared for marketing Prodesse's ProParaflu+(TM) assay, a molecular test that detects and differentiates parainfluenza 1, 2 and 3 viruses, which cause lower respiratory tract infections.

25 Nov 2009

Obese, HIV patients do not respond to antiretroviral therapy, says new study

The immune systems of HIV patients who are obese don't respond to antiretroviral therapy as well as do those of people of normal weight, according to a study conducted by researchers from the Uniformed Services University of the Health Sciences (USU). The findings were presented by San Diego-based Nancy Crum-Cianflone, MD at the annual meeting of the Infectious Diseases Society of America.

25 Nov 2009

MRSA making its way into hospitals, says study

The community-associated strain of the deadly superbug MRSA-an infection-causing bacteria resistant to most common antibiotics-poses a far greater health threat than previously known and is making its way into hospitals, according to a study in the December issue of Emerging Infectious Diseases.

24 Nov 2009

Jubilant Organosys, UAB and Southern Research Institute announce joint venture to accelerate global drug development

Jubilant Organosys, the University of Alabama at Birmingham (UAB), and Southern Research Institute today announced a joint venture that will focus on leveraging their collective innovation and enabling technologies in the areas of Oncology, Metabolic Disease and Infectious Diseases. It is a unique U.S.-India arbitraged and leveraged partnership that will accelerate the development of affordable therapies for patients worldwide.

24 Nov 2009

10 x '20 Initiative calls for global commitment to develop 10 new antibiotics by 2020

The Infectious Diseases Society of America (IDSA) has asked for a commitment from the Obama administration and the European Union to further the Society's mission to achieve the development of 10 new antibiotics within the next 10 years, known as the 10 x '20 Initiative. The World Health Organization (WHO) has identified antimicrobial resistance as one of the three greatest threats to human health.

24 Nov 2009

UT Southwestern Medical Center among 10 institutions to share $56 million from NIH as part of ICAC

UT Southwestern Medical Center is among 10 institutions selected by the National Institutes of Health to share $56 million over five years as part of the Inner City Asthma Consortium (ICAC).

23 Nov 2009

Infectious Diseases News and Research

Roche's MagNA Pure 96 System for nucleic acid purification evaluated

Akonni Biosystems receives $3.2M Phase II SBIR grant from NIH

Centura Health establishes comprehensive trauma system across its regional facilities

Biomagnetics Diagnostics announces Patent License Agreement with Los Alamos National Security

Tripep completes phase I clinical study of its ChronVac-C hepatitis C virus DNA vaccine

WHITIA launches digital medical X-ray device for screening infectious diseases in developing countries

Tripep completes clinical trial of ChronVac-C for Hepatitis C virus treatment

School closure during infectious disease pandemic reduces illness transmission

Merck, Idera Pharmaceuticals extend their vaccine research collaboration

Cells protect themselves against viruses and bacteria with novel non-genetic mechanism

Tibotec Therapeutics' INTELENCE granted FDA traditional approval

WHO investigates cases of H1N1 drug resistance in U.S., Britain

Despite gains, HIV/AIDS remains public-health priority, UNAIDS, WHO say

IES to install electrical systems at the U.S. Army Medical Research Institute of Infectious Diseases

FDA provides marketing clearance for Prodesse's ProParaflu+ assay

Obese, HIV patients do not respond to antiretroviral therapy, says new study

MRSA making its way into hospitals, says study

Jubilant Organosys, UAB and Southern Research Institute announce joint venture to accelerate global drug development

10 x '20 Initiative calls for global commitment to develop 10 new antibiotics by 2020

UT Southwestern Medical Center among 10 institutions to share $56 million from NIH as part of ICAC

NGS for Infectious Disease Surveillance eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News